What type of drug is dasatinib?

Dasatinib is an anti-tumor drug that specifically belongs to the tyrosine kinase inhibitor class of drugs. Dasatinib (Dasatinib) is an oral anti-tumor drug that is widely used in clinical treatment. Dasatinib mainly inhibits the growth and spread of tumor cells by blocking tyrosine protein kinases in intracellular signaling pathways. It can selectively bind to B cell lymphoma2 (B cell chronic lymphocytic leukemia), flt-3 and other receptors, and inhibit their activity, thereby affecting the proliferation, differentiation and viability of tumor cells.

Dasatinib is mainly used to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) patients who are resistant or intolerant to imatinib mesylate, including adult patients in the chronic phase, accelerated phase and blast phase (blast myeloblastosis and blast phase). In addition, the FDA has also approved dasatinib for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) who are resistant or intolerant to other therapies.

The dose of dasatinib is determined based on the patient's specific condition. For example, for patients with Ph+chronic phase CML, the recommended starting dose is dasatinib 100mg, taken orally 1 time per day. For patients with Ph+accelerated phase and blast crisis CML, the recommended starting dose is 70mg, taken 2 times a day, in the morning and evening. Dasatinib tablets should be swallowed whole and should not be crushed or cut. The medication should be taken at the same time, before or after meals. If gastrointestinal discomfort occurs, take with food.

Adverse reactions that may be associated with dasatinib treatment include myelosuppression (such as anemia, neutropenia, and thrombocytopenia), bleeding, fluid retention, QTInterval prolongation, etc. In addition, gastrointestinal symptoms (such as diarrhea, nausea, vomiting, etc.) and rash may also occur. When using dasatinib, it is necessary to closely monitor the patient's hematological parameters and symptom changes to detect and deal with possible adverse reactions in a timely manner.